Telaprevir for HIV/Hepatitis C Virus–Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): An Open-Label, Single-Arm, Phase 2 Trial

Clicks: 180
ID: 273793
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #310 of 1,084 articles by views in clinical infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Retreatment with telaprevir, pegylated interferon, and ribavirin resulted in an 80% sustained virological response rate in HIV/hepatitis C virus–coinfected pati
Reference Key
laurent2014clinicaltelaprevir Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Cotte, Laurent;Braun, Joséphine;Lascoux-Combe, Caroline;Vincent, Corine;Valantin, Marc-Antoine;Sogni, Philippe;Lacombe, Karine;Neau, Didier;Aumaitre, Hugues;Batisse, Dominique;de Truchis, Pierre;Gervais, Anne;Michelet, Christian;Morlat, Philippe;Vittecoq, Daniel;Rosa, Isabelle;Bertucci, Inga;Chevaliez, Stéphane;Aboulker, Jean-Pierre;Molina, Jean-Michel;for the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group;
Journal clinical infectious diseases
Year 2014
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.